immunotherapy

Immune checkpoint inhibitors

A major systemic treatment category in melanoma care, with exact use depending on stage, prior therapy, health, country, and oncology-team judgment.

Plain-English summary

Immunotherapy can help the immune system recognize and attack melanoma, but it can also cause immune-related side effects.

What the sources say

• NCI PDQ lists immune checkpoint inhibitors among systemic treatment categories used in melanoma.
• PD-1 drugs such as nivolumab and pembrolizumab are immunotherapy agents, not MEK inhibitors.
• Prior anti-PD-1/PD-L1 treatment failure is an important fact for later treatment and trial conversations.

When this commonly comes up

• Melanoma is stage III or stage IV.
• Adjuvant, neoadjuvant, or metastatic treatment is being discussed.
• The team is weighing immunotherapy against targeted therapy or trials.

What this does not mean

• It does not mean side effects are mild because the treatment is not chemotherapy.
• It does not mean every patient responds.
• Prior PD-1 / PD-L1 failure changes later treatment discussions.

Important cautions

• Side effects can involve many organs and should be discussed early.
• Prior PD-1/PD-L1 failure changes the next-line conversation.

Questions to ask

• Is immunotherapy being considered before surgery, after surgery, or for metastatic disease?
• What side effects should trigger a call?
• If prior PD-1/PD-L1 treatment failed, what options remain?